53.40
+9.99%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About OBI Pharma
Its shares trade on Taipei Exchange under the ticker 4174.TWO. It has been listed since 12 December 2012. In the fiscal year to 31 December 2025, it reported revenue of TWD 58.6m and a net loss of TWD 2.05bn. At that date it held total assets of TWD 3.42bn and shareholders' equity of TWD 1.89bn.
OBI Pharma, Inc. engages in the development and licensing of novel therapeutic agents for unmet medical needs against cancer. The company is headquartered in Taipei City, Taipei. The company went IPO on 2012-12-12. The firm mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. The company also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. The company is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Dec 2012
- Employees
- 20
- Website
- obipharma.com ↗
Leadership
Pay as last reported
- Mr. Kung-Yee LiangChairman of the Board, since 2023
- Ms. Heidi WangChief Executive Officer, Director, since 2023
- Mr. Colin KaoChief Operating Officer, Corporate Governance Officer, Head of Finance
- Ms. Ya-Chi ChenChief Scientific Officer
- Ms. Melody ChuangHead of Accounting
- Ms. Wan-Fang TingDirector
- Mr. Tamon TsengDirector, since 2012TWD 25,000
- Mr. Ming-Chin ChenIndependent DirectorTWD 340,000
- Tai-tsang ChenIndependent Director
- Mr. Chin-Ting ChiuIndependent DirectorTWD 340,000
- Mr. Howard S. LeeIndependent DirectorTWD 660,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 58
- Environment
- 53
- Social
- 99
- Governance
- 21
- Women in the workforce
- 56.11511%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- OBI Pharma focuses on novel cancer therapies with OBI-822 for metastatic breast cancer.
- OBI-833 targets new generation cancer treatments through therapeutic vaccines.
- OBI-868 is a cancer testing reagent developed for advanced diagnostics.
Weaknesses
- OBI Pharma has only 20 employees limiting R&D capacity.
- The company operates solely in Taipei City with no international presence.
- OBI Pharma's IPO in 2012 shows limited market expansion since then.
Opportunities
- OBI Pharma can expand OBI-822 to treat lung and prostate cancers.
- The company may develop OBI-833 for ovarian and pancreatic cancer treatments.
- OBI-868 testing reagent could enter the global market for cancer diagnostics.
Threats
- OBI Pharma faces competition from other biotech firms in Taipei City.
- The company's reliance on a single product line OBI-822 poses risk.
- OBI-833 development might face regulatory delays in the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.